January 9, 2024

Jitendra Mohan Chief Executive Officer Astera Labs, Inc. 2901 Tasman Drive, Suite 205 Santa Clara, CA 95054

Re: Astera Labs, Inc.
Amendment No. 1 to

Draft Registration Statement on Form S-1

Submitted December

21, 2023

CIK No. 001736297

Dear Jitendra Mohan:

 $\label{eq:weak_problem} \mbox{We have reviewed your amended registration statement and have the following}$ 

comments.

 $\hbox{ Please respond to this letter by amending your registration statement and providing the } \\$ 

requested information. If you do not believe a comment applies to your facts and circumstances  $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left($ 

or do not believe an amendment is appropriate, please tell us why in your response.

 $\label{eq:continuous} \text{ After reviewing any amendment to your registration statement and the information you}$ 

provide in response to this letter, we may have additional comments.

Unless we note otherwise,

any references to prior comments are to comments in our December 7, 2023 letter.

Amendment No. 1 to Draft Registration Statement on Form S-1 Business, page  $85\,$ 

We note your response to our prior comments 10 and 13. Please revise your business section to more fully discuss your dependence on one or a few major customers, including the material terms of your arrangements therewith. In addition, revise your disclosure to more fully and clearly describe the sales and marketing of your products. In this regard, we note your response The Company s distributors and certain of its OEMs and that, ODMs then sell its products to end customers in market globally, and disclosure on page 101 that, We sell and support our products globally through our direct sales force and field applications engineering ( FAE ) team. Please revise to reconcile this apparent inconsistency.

Jitendra Mohan

FirstName LastNameJitendra Mohan

Astera Labs, Inc.

Comapany

January NameAstera Labs, Inc.

9, 2024

January

Page 2 9, 2024 Page 2

FirstName LastName

2. We note your response to our prior comment 11 and reissue it in part. We note disclosure

regarding the importance of artificial intelligence (AI) to your business, including that

your financial performance and growth will be driven in large part by the demand for  ${\tt AI}$ 

workloads. We further note disclosure that broad-based AI adoption is in its early phases  $% \left( 1\right) =\left( 1\right) +\left( 1\right) +$ 

(page 87) and that AI-adoption is likely to continue and may accelerate (page 25). Please  $\,$ 

revise your business section to provide a more balanced discussion of  ${\sf AI.}$  Include, without

limitation, a discussion of the potential limitations, obstacles, and  ${\it uncertainties}$  associated

with AI adoption, use, and commercialization. Additionally revise your risk factors

disclosure as appropriate to discuss any material related risks to the company and  $\ensuremath{\mathsf{Company}}$ 

investors.

Executive Compensation, page 114

3. Please update your compensation disclosure to reflect the fiscal year ended December 31,

2023.

Notes to Consolidated Financial Statements

- 9. Common Stock and Common Stock Warrants, page F-23
- 4. We note your response to comment 18. As noted in ASC 718-10-20, the definition of a

service condition includes those related to "a nonemployee delivering goods or rendering

services to the grantor over a vesting period." Accordingly, please tell us why you believe

customer warrants exercisable based on "specified tranches of global payments" include a

performance condition and not a service condition. As previously requested, considering

your accounting policy to recognize stock-based compensation forfeitures as they occur,

specifically clarify why you do not initially reduce the transaction price for the full  $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left($ 

 $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left($ 

 $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left($ 

 $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left($ 

disclosed on page F-11, please advise and revise your disclosures accordingly.

Please contact Kevin Stertzel at 202-551-3723 or Andrew Blume at 202-551-3254 if you

contact Sarah Sidwell at 202-551-4733 or Jennifer Angelini at 202-551-3047 with any other questions.

Sincerely,

Division of

Corporation Finance

Manufacturing cc: Brad Weber

Office of